{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-082717","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2025-06-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.722165+00:00","generated_at":"2026-05-19T18:31:50.099975+00:00","sec_items":["5.02","5.07","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Nkarta appoints Shawn Rose as CMO & Head of R&D; David Shook resigns effective June 6","bullets":["Shawn Rose, M.D. Ph.D, joins as CMO and Head of R&D starting June 23, 2025, succeeding David Shook.","Dr. Shook resigned to pursue other oncology opportunities; will consult through July 11.","Dr. Rose brings experience from Vividion, Magenta, Janssen, and BMS, with work on Sotyktu, Stelara, Tremfya.","Company reaffirms focus on allogeneic NK cell therapies for autoimmune disease.","Annual meeting results: all three Class II director nominees elected; Ernst & Young ratified as auditor."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-082717","json":"https://secwatch.observer/filing/0000950170-25-082717.json","markdown":"https://secwatch.observer/filing/0000950170-25-082717.md","text":"https://secwatch.observer/filing/0000950170-25-082717.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000095017025082717/0000950170-25-082717-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000095017025082717/nktx-20250603.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T18:31:50.099975+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"50dac225ce","claim":"David Shook resigned as Chief Medical Officer and Head of Research & Development at Nkarta, Inc..","evidence_excerpt":"David Shook, M.D. notified Nkarta, Inc. (the “Company”) of his decision to resign as Chief Medical Officer and Head of Research & Development of the Company to pursue other opportunities in the oncology space.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017025082717/0000950170-25-082717-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer and Head of Research & Development"}],"fact_type":"executive_change"},{"claim_id":"615288b124","claim":"Shawn Rose was appointed as Chief Medical Officer and Head of Research and Development at Nkarta, Inc..","evidence_excerpt":"Shawn Rose, M.D. Ph.D. has been appointed by the Company to succeed Dr. Shook as Chief Medical Officer and Head of Research and Development starting on June 23, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017025082717/0000950170-25-082717-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer and Head of Research and Development"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}